Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
Add more filters










Publication year range
1.
Naunyn Schmiedebergs Arch Pharmacol ; 394(11): 2233-2244, 2021 11.
Article in English | MEDLINE | ID: mdl-34410453

ABSTRACT

Skin fibrosis is a complex biological remodeling process occurring in disease like systemic sclerosis, morphea, or eosinophilic fasciitis. Since the knowledge about the underlying pathomechanisms is still incomplete, there is currently no therapy, which prevents or reverses skin fibrosis sufficiently. The present study investigates the role of polo-like kinase 2 (PLK2) and the pro-fibrotic cytokine osteopontin (OPN) in the pathogenesis of cutaneous fibrosis and demonstrates the antifibrotic effects of systemic mesalazine treatment in vivo. Isolated primary dermal fibroblasts of PLK2 wild-type (WT) and knockout (KO) mice were characterized in vitro. Skin thickness and histoarchitecture were studied in paraffin-embedded skin sections. The effects of mesalazine treatment were examined in isolated fibroblasts and PLK2 KO mice, which were fed 100 µg/g mesalazine for 6 months via the drinking water. Compared to WT, PLK2 KO fibroblasts displayed higher spontaneous myofibroblast differentiation, reduced proliferation rates, and overexpression of the fibrotic cytokine OPN. In vitro, 72 h of treatment with 10 mmol/L mesalazine induced phenotype conversion in PLK2 KO fibroblasts and attenuated OPN expression by inhibiting ERK1/2. In vivo, dermal myofibroblast differentiation, collagen accumulation, and skin thickening were prevented by mesalazine in PLK2 KO. Plasma creatinine levels indicated good tolerability of systemic long-term mesalazine treatment. The current study reveals a spontaneous fibrotic skin phenotype and ERK1/2-dependent OPN overexpression in PLK2 KO mice. We provide experimental evidence for the antifibrotic effectiveness of systemic mesalazine treatment to prevent fibrosis of the skin, suggesting further investigation in experimental and clinical settings.


Subject(s)
Fibroblasts/drug effects , Mesalamine/pharmacology , Protein Serine-Threonine Kinases/genetics , Skin/drug effects , Animals , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Anti-Inflammatory Agents, Non-Steroidal/toxicity , Cell Differentiation/drug effects , Collagen/metabolism , Creatinine/blood , Disease Models, Animal , Female , Fibroblasts/pathology , Fibrosis/prevention & control , Male , Mesalamine/administration & dosage , Mesalamine/toxicity , Mice , Mice, Knockout , Osteopontin/genetics , Skin/pathology
2.
Int J Toxicol ; 39(3): 241-247, 2020.
Article in English | MEDLINE | ID: mdl-32308077

ABSTRACT

Mesalazine is widely used in the management of inflammatory bowel disease. Previous studies reported that mesalazine-induced cardiotoxicity is a rare, potentially fatal complication. Mitochondria play an important role in myocardial tissue homeostasis. Deterioration in mitochondrial function will eventually lead to cardiomyocyte death and consequently cardiovascular dysfunction. The aim of the current study was to investigate the effects of mesalazine on rat heart mitochondria. Rat heart mitochondria were isolated by mechanical lysis and differential centrifugation. Parameters of mitochondrial toxicity including succinate dehydrogenase (SDH) activity, reactive oxygen species (ROS) formation, mitochondrial membrane potential (MMP) collapse, mitochondrial swelling, and cytochrome c release were evaluated. Results revealed that mesalazine induced a concentration- and time-dependent rise in mitochondrial ROS formation, inhibition of SDH, MMP collapse, mitochondrial swelling, and cytochrome c release in rat heart mitochondria. These results indicate that the cardiotoxic effects of mesalazine are most likely associated with mitochondrial dysfunction and ROS formation, which finally ends in cytochrome c release signaling and induction of apoptosis.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/toxicity , Cardiotoxins/toxicity , Mesalamine/toxicity , Mitochondria, Heart/drug effects , Animals , Cardiotoxicity/etiology , Cardiotoxicity/metabolism , Cardiotoxicity/physiopathology , Cytochromes c/metabolism , Male , Membrane Potential, Mitochondrial/drug effects , Mitochondria, Heart/metabolism , Mitochondria, Heart/physiology , Oxidative Stress/drug effects , Rats, Wistar , Reactive Oxygen Species/metabolism
3.
Food Chem Toxicol ; 97: 150-158, 2016 Nov.
Article in English | MEDLINE | ID: mdl-27587080

ABSTRACT

Our previous study demonstrated that a combination of alternative medicine berberine and conventional 5-aminosalicylic acid (5-ASA) showed promise to be a novel therapeutic strategy for ulcerative colitis (UC). This present study aims to sketch the pre-clinical toxicity profile of this combination (1:10 dose ratio) on mice. In acute toxicity test, the determined median lethal dose (LD50) was 278.7 mg/kg berberine plus 2787 mg/kg 5-ASA. The results from subacute toxicity test demonstrated that no toxic signs of clinical symptoms, no significant changes in hematological or biochemical parameters were detected in mice treated with 14 + 140, 28 + 280 or 56 + 560 mg/kg of berberine plus 5-ASA treatment. Histological examinations revealed that accompanied with an increase in spleen weight, frequently recorded enlargement and white pulp hyperplasia of spleen were detected in mice when exposed to three doses of combination treatments. Further in vitro assessment suggested that the spleen toxicity was originated from berberine by its inhibition in cell viability and cell proliferation of lymphocytes. The results of this study indicate that the combination of berberine and 5-ASA shows a slight toxic effect on spleen, suggesting that this combination should be used with caution for patients.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/toxicity , Berberine/toxicity , Erythrocytes/pathology , Lymphocytes/pathology , Mesalamine/toxicity , Toxicity Tests/methods , Administration, Oral , Animals , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Berberine/administration & dosage , Drug Combinations , Drug Evaluation, Preclinical , Erythrocytes/drug effects , Female , Lymphocytes/drug effects , Male , Mesalamine/administration & dosage , Mice , Mice, Inbred ICR
5.
Pharmazie ; 69(9): 676-9, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25272938

ABSTRACT

We investigated whether nano-sized polystyrene particles affect drug-induced toxicity. The particles, which are widely used industrially, had diameters of 50 (NPP50), 200 (NPP200) or 1000 (NPP1000) nm. The toxic chemicals tested were acetaminophen (APAP), 5-aminosalicylic acid (5-ASA), tetracycline (TC), and sodium valproate (VPA). All treatments in the absence of the nanoparticles were non-lethal and did not result in severe toxicity. However, when mice were injected with APAP, 5-ASA or TC together with polystyrene particles, synergistic, enhanced toxicity was observed in mice injected with NPP50. These synergic effects were not observed in mice co-injected with NPP200 or NPP1000. On the other hand, co-administration of VPA and NPP50, NPP200 or NPP1000 did not elevate toxicity. The results show that NPP50 differs in hepatotoxicity depending on the drug co-administered. These findings suggest that further evaluation of the interactions between polystyrene nanoparticles and drugs is a critical prerequisite to the pharmaceutical application of nanotechnology.


Subject(s)
Acetaminophen/toxicity , Analgesics, Non-Narcotic/toxicity , Anti-Bacterial Agents/toxicity , Anti-Inflammatory Agents, Non-Steroidal/toxicity , Mesalamine/toxicity , Nanoparticles/toxicity , Polystyrenes/toxicity , Tetracycline/toxicity , Alanine Transaminase/blood , Animals , Aspartate Aminotransferases/blood , Blood Urea Nitrogen , Male , Mice , Mice, Inbred BALB C , Particle Size
6.
Pharmazie ; 66(4): 282-6, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21612156

ABSTRACT

Exposure to nano-sized particles is increasing because they are used in a wide variety of industrial products, cosmetics, and pharmaceuticals. Some animal studies indicate that such nanomaterials may have some toxicity, but their synergistic actions on the adverse effects of drugs are not well understood. In this study, we investigated whether 70-nm silica particles (nSP70), which are widely used in cosmetics and drug delivery, affect the toxicity of a drug for inflammatory bowel disease (5-aminosalicylic acid), an antibiotic drug (tetracycline), an antidepressant drug (trazodone), and an antipyretic drug (acetaminophen) in mice. Co-administration of nSP70 with trazodone did not increase a biochemical marker of liver injury. In contrast, co-administration increased the hepatotoxicity of the other drugs. Co-administration of nSP70 and tetracycline was lethal. These findings indicate that evaluation of synergistic adverse effects is important for the application of nano-sized materials.


Subject(s)
Acetaminophen/toxicity , Analgesics, Non-Narcotic/toxicity , Anti-Bacterial Agents/toxicity , Anti-Inflammatory Agents, Non-Steroidal/toxicity , Mesalamine/toxicity , Selective Serotonin Reuptake Inhibitors/toxicity , Silicon Dioxide/chemistry , Tetracycline/toxicity , Trazodone/toxicity , Acetaminophen/chemistry , Alanine Transaminase/blood , Analgesics, Non-Narcotic/chemistry , Animals , Anti-Bacterial Agents/chemistry , Anti-Inflammatory Agents, Non-Steroidal/chemistry , Aspartate Aminotransferases/blood , Blood Urea Nitrogen , Injections, Intraperitoneal , Male , Mesalamine/chemistry , Mice , Mice, Inbred BALB C , Nanoparticles , Selective Serotonin Reuptake Inhibitors/chemistry , Tetracycline/chemistry , Trazodone/chemistry
8.
Toxicology ; 280(3): 71-6, 2011 Feb 27.
Article in English | MEDLINE | ID: mdl-21115095

ABSTRACT

Mesalamine is the first line pharmacologic intervention for patients with ulcerative colitis, and recent epidemiologic studies have demonstrated a protective association between therapeutic use of the drug and colorectal carcinoma. However, the mechanism by which this protection is afforded has yet to be elucidated. Because copper is found at higher than normal concentrations in neoplastic cell nuclei and is known to interact with phenolic compounds to generate reactive oxygen species, we investigated whether the reaction of mesalamine/copper was able to induce oxidative DNA strand breaks in φX-174 RF I plasmid DNA, and the various components of the mechanism by which the reaction occurred. Plasmid DNA strand breaks were induced by pharmacologically relevant concentrations of mesalamine in the presence of a micromolar concentration of Cu(II), and damage was inhibited by bathocuproinedisulfonic acid (BCS) and catalase. Further, we showed that the reaction of copper with mesalamine consumed molecular oxygen, which was inhibited by BCS. Electron paramagnetic resonance spectral analysis of the reaction of copper/mesalamine indicated the presence of the hydroxyl radical, which was inhibited by both BCS and catalase. This study demonstrates for the first time that through a copper-redox cycling mechanism, the copper-mediated oxidation of mesalamine is a pro-oxidant interaction that generates hydroxyl radicals which may participate in oxidative DNA damage. These results demonstrate a potential mechanism of the anticancer effects of mesalamine in patients with ulcerative colitis.


Subject(s)
Antineoplastic Agents/toxicity , Copper/toxicity , DNA Damage/drug effects , Mesalamine/toxicity , Oxidative Stress/drug effects , Reactive Oxygen Species/toxicity , Antineoplastic Agents/pharmacokinetics , Copper/pharmacokinetics , DNA Damage/physiology , Dose-Response Relationship, Drug , Drug Interactions/physiology , Humans , Mesalamine/pharmacokinetics , Oxidation-Reduction/drug effects , Oxidative Stress/physiology , Reactive Oxygen Species/metabolism
9.
Hum Exp Toxicol ; 30(7): 772-6, 2011 Jul.
Article in English | MEDLINE | ID: mdl-20670990

ABSTRACT

Drugs containing 5-acetylsalicylic acid (5-ASA) have been commonly used for inflammatory bowel diseases for more than half a century, but no case about overdose of suppository form of mesalazine which was taken both orally and rectally has been reported in the related literature up to now. In the present case, a 20-year-old male patient who took 14.5 g of mesalazine rectally and orally for suicide purpose is discussed. He was an ulcerative colitis patient and depressed about his illness and routine life traffic. Although it was hard for him to take the suppository form orally because of its bad taste and structure, he took it with the help of water. In the patient's colonoscopy, diffuse hyperemia and edema extending from the anal channel to the proximal rectal mucosa and a 1.5 cm diameter ulcer expanding from anal channel through the rectum were identified. No pathology was found in the upper gastrointestinal endoscopy. Routine laboratory examination was performed and no abnormality was identified in the patient's total blood account, biochemical parameters and full-urine examination. In the control rectoscopy applied to the patient 15 days later, recovery of the ulcer was observed and he was discharged to be followed in the psychiatry clinic.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/toxicity , Mesalamine/toxicity , Poisoning/etiology , Suicide, Attempted , Administration, Oral , Administration, Rectal , Anti-Ulcer Agents/therapeutic use , Charcoal/administration & dosage , Colitis, Ulcerative/drug therapy , Colitis, Ulcerative/pathology , Colonoscopy , Drug Overdose , Fluid Therapy , Gastric Lavage , Humans , Male , Poisoning/pathology , Poisoning/therapy , Sucralfate/therapeutic use , Suppositories , Treatment Outcome , Young Adult
11.
Arch Pharm Res ; 31(6): 736-41, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18563355

ABSTRACT

Anti-inflammatory effects of three potassium salts of N,N-disubstituted 4-aminoazobenzenesulfonic acids were investigated and compared to that of acetylsalicylic acid (ASA) in rats with adjuvant arthritis (AA). Prophylactic oral administration of all compounds in a dose of 150 mg/kg ameliorated AA symptoms in animals. The most pronounced anti-inflammatory activity at the end of the experiment showed compound 1 containing imino group: it significantly suppressed joint swelling by 48.2% in female and by 44.2% in male rats with AA. The development of polyarthritis after the treatment with this compound was the lowest in female (20%) and male (40%) rats (in control--100% of animals with polyarthritis). All derivatives, and especially compound 1, also improved the systemic parameters of disease such as blood indices and internal organs' weight, and showed no toxicity on the main organs such as liver and spleen.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Arthritis, Experimental/prevention & control , Benzenesulfonates/pharmacology , Mesalamine/pharmacology , Administration, Oral , Animals , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/toxicity , Arthritis, Experimental/chemically induced , Arthritis, Experimental/pathology , Benzenesulfonates/administration & dosage , Benzenesulfonates/toxicity , Female , Freund's Adjuvant , Hematologic Tests , Joints/drug effects , Joints/pathology , Male , Mesalamine/administration & dosage , Mesalamine/toxicity , Organ Size , Rats , Rats, Inbred Lew
12.
Arch Pharm Res ; 28(6): 637-47, 2005 Jun.
Article in English | MEDLINE | ID: mdl-16042070

ABSTRACT

This work includes the synthesis of 15 final compounds (6a-h and 7b-h) as prodrugs of 5-ASA in the form of the acid itself, esters and amides linked by an amide linkage through a spacer to the endocyclic ring N of nicotinamide. Also, 15 new intermediate compounds were prepared. The target compounds (6b, 6f, 7b, and 7e-h) revealed potent analgesic and anti-inflammatory activities in comparison to sulfasalazine and 5-ASA. In addition, ulcerogenicity, LD50, in vivo and in vitro metabolism of compound 7f were determined.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Mesalamine/chemistry , Prodrugs/pharmacology , Salicylamides/pharmacology , Salicylates/pharmacology , Analgesics/chemical synthesis , Analgesics/pharmacology , Analgesics/toxicity , Animals , Anti-Inflammatory Agents, Non-Steroidal/chemical synthesis , Anti-Inflammatory Agents, Non-Steroidal/toxicity , Carrageenan , Drug Stability , Edema/prevention & control , Feces/chemistry , Gastrointestinal Contents/microbiology , Hydrogen-Ion Concentration , Lethal Dose 50 , Magnetic Resonance Spectroscopy , Male , Mesalamine/pharmacology , Mesalamine/toxicity , Mice , Pain/prevention & control , Prodrugs/chemical synthesis , Prodrugs/toxicity , Rats , Salicylamides/chemical synthesis , Salicylamides/toxicity , Salicylates/chemical synthesis , Salicylates/toxicity , Stomach Ulcer/chemically induced , Streptococcus pyogenes/metabolism , Structure-Activity Relationship
13.
Int J Oncol ; 17(1): 173-9, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10853036

ABSTRACT

Non-steroidal anti-inflammatory drugs (NSAIDs) including aspirin have been shown to suppress colon carcinogenesis and in some cases reduce the size of colorectal polyps. Balsalazide disodium (BSZ) is a colon-specific prodrug of the salicylate, 5-aminosalicylic acid. The aim of the present study was to test the chemopreventive activity of BSZ in two established animal models of colon tumorigenesis, azoxymethane-induced aberrant crypt formation in the rat and intestinal tumor formation in the B6-Min/+ mouse. Aberrant crypt foci (ACF) were induced in Fischer 344 rats via 2 subcutaneous injections of azoxymethane (20 mg/kg). BSZ was supplied in the drinking water for 8 weeks and ACF quantitated. B6-Min/+ mice were treated from 55 days of age for 90 days and intestinal tumors scored for number, size and location. BSZ treatment of AOM-injected rats reduced ACF formation in a dose-dependent manner by 60% with the greatest effect observed on ACF with 4 or more crypts. In B6-Min/+ mice a dose-dependent reduction of intestinal tumor number was observed which reached 80% in the distal small intestine and colon. A preliminary mechanistic study in cultured human colon cancer cells showed that both BSZ and 5-ASA inhibited colon cancer cell proliferation in vitro. However, 5-ASA but not BSZ produced changes consistent with the induction of apoptosis. BSZ produces a dose-dependent chemopreventive effect on colon carcinogenesis. A possible mechanism is consistent with the inhibition of cellular proliferation and the induction of apoptosis.


Subject(s)
Aminosalicylic Acids/pharmacology , Anti-Ulcer Agents/pharmacology , Anticarcinogenic Agents/pharmacology , Azoxymethane/toxicity , Colonic Neoplasms/prevention & control , Intestinal Mucosa/drug effects , Intestinal Neoplasms/prevention & control , Aminosalicylic Acids/toxicity , Animals , Cell Division/drug effects , Colonic Neoplasms/chemically induced , Colonic Neoplasms/pathology , Genes, APC , Humans , Indomethacin/toxicity , Intestinal Mucosa/pathology , Intestinal Neoplasms/chemically induced , Intestinal Neoplasms/pathology , Mesalamine/toxicity , Mice , Mice, Mutant Strains , Phenylhydrazines , Prodrugs/toxicity , Rats , Rats, Inbred F344 , Tumor Cells, Cultured
14.
J Toxicol Sci ; 23 Suppl 3: 539-52, 1998 Jul.
Article in Japanese | MEDLINE | ID: mdl-9760411

ABSTRACT

A two stage carcinogenesis promotion test using phenobarbital (PB) as a positive control was performed on mesalazine in rats (F344,male). Pathological and immunohistological examinations were performed to examine the cell damage and proliferation in the liver and kidneys. As the initiation treatment, groups 1,2,3 and 5 were administered 300 mg/kg diethylnitrosamine (DEN)dissolved in 0.9% physiological saline, and group 4 was administered 5 ml/kg 0.9% physiological saline once intraperitoneally. Then group 1 was orally administered a water solution (5 ml/kg) containing 0.5% CMC-Na, and groups 2,3 and 4 similar water solution but containing 150, 300 and 300 mg/kg mesalazine, respectively. Group 5 was administered 0.05% PB mixed in feed from weeks 2 to 8. Partial (2/3) hepatectomy was performed in all 5 groups at week 3 after DEN administration. NO clear differences between the groups were observed in general conditions, body weight or amount of food consumption. The number or area-size of hepatic GST-P positive altered cell foci revealed no significant differences between groups 1,2 and 3, but a significant increase in number and area-size was observed in group 5. No GST-P positive cell foci were detected in group 4. The number of altered cell foci (H.E. staining) in the DENgroups administered mesalazine was the same as that in group 1. Thus, mesalazine did not promote hepatocarcinogenesis in the present experimental system. Statistically insignificant appearances of basophilic and acidophilic changes were observed in the renal tubular epithelium and mineral deposits in the renal papillary region and cortical margin region. The PCNA labeling rate was significantly lower in group 4, corresponding with the histological finding showing no proliferation of the renal tubular epithelium. Judging from the above test results, mesalazine was likely to show neither a promotion effect on the initiation induced by DEN nor cell proliferative activity on the kidneys by administration for this experimental period.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/toxicity , Liver/drug effects , Mesalamine/toxicity , Administration, Oral , Animals , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Body Weight/drug effects , Carcinogenicity Tests/methods , Eating/drug effects , Kidney/drug effects , Male , Mesalamine/administration & dosage , Rats , Rats, Inbred F344
15.
Cell Biol Toxicol ; 13(6): 445-51, 1997 Oct.
Article in English | MEDLINE | ID: mdl-9352122

ABSTRACT

Nonsteroidal anti-inflammatory drugs can cause serious side-effects such as tubulo-interstitial nephritis. Mesalazine (5-ASA, 5-aminosalicylic acid) is used for the treatment of colitis ulcerosa, Crohn disease, and other diseases; it has been found to induce necrosis of both proximal convoluted tubules and renal papillaries. The comparative cytotoxicity of 3-, 4-, and 5-aminosalicylic acid, acetylsalicylic acid (AcSA), and the parent compound salicylic acid (SA) was investigated for the free acids and for their sodium salts. The interaction with endogenous glutathione (GSH) was also investigated. Four established cell lines were used: MDCK, LLC-PK1, NRK as renal cells, and HepG2 as hepatic cells. The free acid compounds were less toxic than their corresponding salts. Acidic 5-ASA was the most toxic of the three isomers in MDCK and LLC-PK1 cells, while NRK and HepG2 were more susceptible to acidic 3-ASA. Addition of NaOH modified the relative toxicity of 3-ASA and 5-ASA. The LLC-PK1 and HepG2 cells were more sensitive to the test chemicals as their salts than were the NRK and MDCK cells. SA and 5-ASA decreased the GSH content in renal cells and increased it in HepG2. GSH depletion with L-buthionine-(S,R)-sulfoximine enhanced the toxicity only for SA in NRK and for 5-ASA and AcSA in HepG2. No correlation between endogenous GSH and the susceptibility of MDCK and LLC-PK1 to the test compounds was observed. The results suggest that no typical nephrotoxic effect occurred. No explanation could be found for the tubulo-interstitial nephritis caused by 5-ASA therapy.


Subject(s)
Aminosalicylic Acid/toxicity , Anti-Inflammatory Agents, Non-Steroidal/toxicity , Aspirin/toxicity , Mesalamine/toxicity , Salicylates/toxicity , Animals , Aspirin/chemistry , Cell Line/drug effects , Dogs , Glutathione/analysis , Humans , Kidney Tubules/drug effects , Neutral Red , Rats , Salicylates/chemistry , Salicylic Acid , Structure-Activity Relationship , Swine , Tumor Cells, Cultured/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...